| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | -0.068 | 0.04 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.065 | 0.04 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | -0.071 | 0.04 |
| mRNA | SMER-3 | CTRPv2 | pan-cancer | AAC | -0.076 | 0.04 |
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | -0.063 | 0.04 |
| mRNA | BRD-K92856060 | CTRPv2 | pan-cancer | AAC | -0.071 | 0.04 |
| mRNA | HG-5-88-01 | GDSC1000 | pan-cancer | AAC | 0.093 | 0.04 |
| mRNA | SB-743921 | CTRPv2 | pan-cancer | AAC | -0.064 | 0.04 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.068 | 0.04 |
| mRNA | KU 0060648 | CTRPv2 | pan-cancer | AAC | -0.069 | 0.05 |